Transgenic cancer models in fish
The present invention provides transgenic fish whose genome has stably-integrated therein an oncogene operably linked to a promoter. Methods of making the transgenic fish and methods for their use are also provided. In one embodiment, the transgenic fish may advantageously be utilized in methods of screening for drugs or agents that modulate oncogene-mediated neoplastic or hyperplasic transformation, or that modulate sensitivity to chemotherapy or radiation therapy. In another embodiment, the transgenic fish may be used methods of identifying mutations that modulate oncogene-mediated neoplastic or hyperplastic transformation, or that modulate sensitivity to chemotherapy or radiation therapy.
1. A transgenic fish whose genome comprises a transgene encoding cMYC oncogene operably linked to a RAG2 promoter, wherein the oncogene is expressed in T-lymphocytes and induces T-cell acute lymphoblastic leukemia.
2. The transgenic fish of claim 1 , wherein the cMYC oncogene is fused to a reporter gene.
3. The transgenic fish of claim 2 , wherein the reporter gene is a fluorescent protein gene.
4. The transgenic fish of claim 3 , wherein the fluorescent protein gene is GFP.
5. The transgenic fish of claim 1 , wherein the cMYC oncogene is fused to ER.
6. The transgenic fish of claim 5 , wherein the ER is tamoxifen-sensitive ER (ER™).
7. The transgenic fish of claim 1 , wherein the transgenic fish is a transgenic zebrafish.
8. A method of screening test drugs or agents that suppress cMYC oncogene-induced leukemia, comprising:
contacting or otherwise exposing a transgenic fish to a test drug or agent, wherein the transgenic fish has a genome that comprises a transgene encoding mouse cMYC oncogene operably linked to a RAG2 promoter, and wherein expression of the oncogene in T-lymphocytes induces T-cell acute lymphoblastic leukemia;
comparing the leukemia in said transgenic fish after contact or exposure to said test drug or agent relative to the leukemia of said fish prior to contact or exposure with said test drug or agent;
wherein suppression of the leukemia in said transgenic fish after contact or exposure to said test drug or agent relative to the leukemia of said fish prior to contact or exposure with said test drug or agent is indicative of a test drug or agent that suppresses cMYC-induced leukemia.
9. The method of claim 8 , wherein the comparison step comprises measuring the rate of onset of tumor formation resulting from cMYC oncogene-induced leukemia.
10. The method of claim 8 , wherein the comparison step comprises measuring the amount or size of tumors resulting from cMYC oncogene-induced leukemia.
11. The method of claim 8 , wherein the test drug or agent is antisense DNA, antisense RNA, or small interfering RNA.
12. The method of claim 8 , wherein the transgenic fish is a transgenic fish embryo.
13. The method of claim 8 , wherein the transgenic fish is a transgenic zebrafish.
14. The method of claim 12 , wherein the transgenic fish embryo is a transgenic zebrafish embryo.